Loading...
•
Sep 30, 2021
Tandem Diabetes Q3 2021 Earnings Report
Reported a strong third-quarter performance with increased pump shipments and sales, and improved gross and operating margins.
Key Takeaways
Tandem Diabetes Care announced strong Q3 2021 results with a 45% increase in sales to $179.6 million and a significant rise in worldwide pump shipments by 43%. The company also updated its full-year sales guidance to $685 million - $695 million.
Worldwide pump shipments increased 43 percent to 31,558 pumps.
Sales increased 45 percent to $179.6 million.
Gross margin improved to 54 percent of sales.
Operating margin improved to 4 percent of sales.
Revenue by Geographic Location
Forward Guidance
Tandem Diabetes Care updated its financial guidance for the year ending December 31, 2021.
Positive Outlook
- Sales are estimated to be in the range of $685 million to $695 million, representing 37% to 39% annual sales growth compared to 2020.
- International sales are projected to be approximately $168 million to $173 million, indicating 102% to 108% annual sales growth compared to 2020.
- Gross margin is estimated to be approximately 54%.
- Adjusted EBITDA is estimated to be approximately 15% of sales.
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $75 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...